Search

Gacyclidine

Gacyclidine has been used in trials studying the treatment of Tinnitus.

Influenza A virus A/Washington/19/2020 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)

Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

NNZ-2591

It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019. … [L11100] Clinical trials are expected to begin in 2020.[L11103,L11100]

Posizolid

Posizolid (AZD2563) is an oxazolidinone antibiotic. … In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though

Noscapine

Flortaucipir

Flortaucipir is under investigation in clinical trial NCT03507257 (Longitudinal Early-onset Alzheimer's Disease Study Protocol).

Alacepril

The usage of the INN stem '-pril' in the name indicates that Alacepril is a angiotensin-converting enzyme inhibitor. Alacepril has a monoisotopic molecular weight of 406.16 Da.

Enzastaurin

Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of

Zolasartan

The usage of the INN stem '-sartan' in the name indicates that Zolasartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).

Emricasan

Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. … It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.